BPC-157 Capsules

Oral capsule presentation of BPC-157. Bioavailability, stability, and regulatory classification of capsule formats are unresolved.

No assumption should be made that oral formulation reproduces effects observed in injectable, cellular, or animal research.

Current literature places BPC-157 Capsules at Evidence Level IV, predominantly animal and cellular evidence.

Evidence Level IV

Bioavailability, stability, intended-use implications, and regulatory classification are unresolved.

Safety and toxicology data are limited; consult the primary literature for model-specific findings.

Investigational research material; not an approved drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.